Battle Card: TRIO Pharmaceuticals Sales Trigger

Do not index

🚀 Battle Card: TRIO Pharmaceuticals

Quick trigger:

Pro Tip: This TRIO Pharmaceuticals sales trigger is your green light to engage their R&D and decision team now.

👤 Decision Maker in the News

Mikael Dolsten, M.D., Ph.D., Chairman of the Board of Directors · 🔗 [LinkedIn](https://www.linkedin.com/company/trio-pharmaceutials-inc/?viewAsMember=true)

💡 Why It Matters

Bringing in a veteran CSO and R&D leader slashes time-to-clinic risk and boosts investor confidence. → Source

🎯 Core Pain Point

Accelerating preclinical to IND-enabling studies

Differentiating TRAILBody™ platform in a crowded oncology antibody market

💰 What to Pitch

Primary: High-throughput antibody screening services → accelerate candidate nomination and optimization

Expansion: Regulatory strategy consulting → streamline IND submissions and reduce review cycles

🗺️ Quick Context

HQ: San Carlos, CA

Employees: ≈ 30

Rev: ≈ $0 M (pre-revenue)

Website: [www.triopharmaceuticals.com](https://www.triopharmaceuticals.com/)

🤼 Competitive Intel

Which other vendors you’ll probably face to win TRIO Pharmaceuticals’s business.

Charles River Laboratories — Preclinical CRO

Unique edge: Integrated in vivo oncology models
Evaluated by R&D for translational relevance

WuXi AppTec — Preclinical CRO

Unique edge: Global assay & biomanufacturing platforms
Evaluated by CSO for scalability

Catalent — CMC & Manufacturing

Unique edge: End-to-end GMP support
Evaluated by Dir. of Ops for manufacturing readiness

✅ Do-Now Checklist

Connect with the decision maker on LinkedIn (link above)

Generate email referencing this TRIO Pharmaceuticals sales trigger with the Copy-My-Prompt block (Step 7) and send first touch

Schedule follow-ups in CRM (Day 3 & Day 10)

Next Step

Get TRIO Pharmaceuticals sales trigger intel like this daily—no fluff, all pipeline. Subscribe to NewsletterForLeads

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑≈ TBD❑
OFFER_BRIEF   = ❑High-throughput antibody screening services❑
PROOF_METRIC  = ❑40% faster candidate nomination❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑friendly❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Mikael
COMPANY     = TRIO Pharmaceuticals
DEPT        = R&D
SIZE        = ≈30
BOTTLENECK  = Accelerating preclinical to IND-enabling studies
EVENT       = Mikael Dolsten joins as Chairman
DETAIL      = TRAILBody™ antibodies kill tumor cells without toxic payload
PAIN        = current antibody therapies face relapses and resistance reducing response
SRC         = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20251008112766&div=41152219
SIM_CO      = Genentech
WIN_METRIC  = 40% faster candidate nomination
NEXT_SIZE   = 50
EMP_EST     = ≈30
REV_EST     = ≈0 M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: ≈30-person R&D

Mikael—noticed your R&D team is ≈30.

That’s when Accelerating preclinical to IND-enabling studies slows growth.

We helped Genentech fix this with High-throughput antibody screening services.

Result: 40% faster candidate nomination.  
Quick call?

PS—next bottleneck hits ≈50.

DM ≤45 words, TONE:
Saw your post about TRAILBody™ antibodies kill tumor cells without toxic payload — current antibody therapies face relapses and resistance reducing response.  
High-throughput antibody screening services. 40% faster candidate nomination.  
Quick chat?```

Battle Card: TRIO Pharmaceuticals Sales Trigger